Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rifampicin Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

NCT04301310
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986235 (Treatment A), Rifampin (Treatment B)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Fruquintinib, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

NCT01591850
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Fluconazole, Rifampin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

NCT02608034
View directory record Official record
Conditions
Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions
Itraconazole, Rifampin, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

NCT02846519
View directory record Official record
Conditions
Healthy
Interventions
Esketamine, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 2, 2026, 10:55 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement

NCT06489431
View directory record Official record
Conditions
Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation
Interventions
Chlorhexidine, Gentamicin, Rifampin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Mountain View, California • Chicago, Illinois • Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

NCT06363630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Itraconazole, Rifampin, Golcadomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

NCT01395927
View directory record Official record
Conditions
Healthy
Interventions
Rifampin, Canagliflozin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

NCT02804399
View directory record Official record
Conditions
Healthy
Interventions
PF-06463922, rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r), Rifampin (RIF)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 2, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

NCT04312282
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Tesetaxel, Itraconazole, Rifampin
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

NCT03712540
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

NCT02563327
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 10:55 AM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

NCT01169038
View directory record Official record
Conditions
Pulmonary Sarcoidosis, Lung Function
Interventions
levaquin; ethambutol; rifampin and azithromycin.
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

NCT00621309
View directory record Official record
Conditions
Adverse Drug Interactions
Interventions
Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Trial of High-Dose Rifampin in Patients With TB

NCT01408914
View directory record Official record
Conditions
Tuberculosis
Interventions
Higher-Dose Rifampin
Drug
Lead sponsor
Harvard University Faculty of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 2, 2026, 10:55 AM EDT
Terminated Phase 4 Interventional Results available

Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children

NCT00370149
View directory record Official record
Conditions
Infection Prevention
Interventions
Antibiotic-impregnated Catheters (M/R), Non-impregnated Catheters (C/S)
Device
Lead sponsor
Indiana University
Other
Eligibility
Up to 17 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

NCT02430545
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

NCT03311841
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 78 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 2, 2026, 10:55 AM EDT